The trial analysed Lomecel-B to treat mild Alzheimer’s disease. Credit: Lightspring / Shutterstock.

Longeveron has revealed that the Phase IIa CLEAR MIND clinical trial of Lomecel-B for treating mild Alzheimer’s disease met its primary safety and secondary efficacy endpoints.

The placebo-controlled, randomised trial enrolled 48 participants aged between 60 and 85 years with mild Alzheimer’s disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The trial indicated that the treatment with Lomecel-B could potentially slow disease progression.

Furthermore, Lomecel-B was found to be safe for both single and multiple dosing regimens, without any cases of hypersensitivity or infusion-related reactions and amyloid-related imaging abnormalities (ARIA) observed.

Patients receiving Lomecel-B also showed a general slowing of disease worsening compared to the placebo arm.

The therapeutic potential of Lomecel-B was supported by changes from baseline at week 39 in the Composite Alzheimer’s Disease Score (CADS), which includes cognitive, functional capacity, and brain MRI measurements.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Significant statistical results were noted in the Montreal Cognitive Assessment for patients treated with Lomecel-B, with trends indicating improvements in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and the Mini-Mental State Examination (MMSE) versus placebo.

The Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale also showed a statistically significant improvement relative to placebo.

The US Food and Drug Administration (FDA) previously awarded Lomecel-B both regenerative medicine advanced therapy and fast-track designations for mild Alzheimer’s disease treatment.

Longeveron co-founder, chief science officer and chairman Joshua Hare said: “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of mild Alzheimer’s disease and suggest, with further clinical evaluation, that this cellular therapy has the potential to have a positive impact on patients afflicted with this devastating disease.

“We look forward to meeting the FDA to review this data and discuss the future development path for Lomecel-B in Alzheimer’s disease.”